Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

PHGUF Stock  USD 0.75  0.07  8.54%   
Roughly 62% of Pharming Group's investor base is looking to short. The analysis of overall sentiment of trading Pharming Group NV pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Pharming Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets.
Pharming Group pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Pharming daily returns and investor perception about the current price of Pharming Group NV as well as its diversification or hedging effects on your existing portfolios.
  
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Marketscreener.com

Read at news.google.com
Google News at Macroaxis
  

Pharming Group Fundamental Analysis

We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Pharming Group is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Peers

Trending Equities

BBY  3.50   
0%
100.0%
TGT  2.81   
0%
80.0%
UPS  2.63   
0%
75.0%
HD  2.33   
0%
66.0%
MET  1.64   
0%
46.0%
CVS  1.59   
0%
45.0%
WFC  1.51   
0%
43.0%
S  1.46   
0%
41.0%
C  1.29   
0%
36.0%
AAL  1.27   
0%
36.0%
T  0.87   
0%
24.0%
AAPL  0.59   
0%
16.0%
CVX  0.45   
0%
12.0%
IBM  0.26   
0%
7.0%
INTC  0.25   
0%
7.0%
AA  2.11   
60.0%
0%

Complementary Tools for Pharming Pink Sheet analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities